CCT6A is a subunit of the TRiC (chaperonin-containing T-complex), a molecular chaperone that assists in folding actin, tubulin, and other proteins through ATP hydrolysis 1. The TRiC complex mediates folding of WRAP53/TCAB1 to regulate telomere maintenance 1. Beyond canonical chaperone functions, CCT6A exhibits oncogenic roles in multiple cancers. In lung adenocarcinoma, CCT6A is overexpressed and promotes progression via the STAT1/HK2 axis, enhancing aerobic glycolysis and cell proliferation 2. CCT6A is coamplified with EGFR in lung adenocarcinoma and predicts unfavorable survival outcomes 3. In triple-negative breast cancer, CCT6A activates PI3K/AKT signaling to promote migration, invasion, and epithelial-mesenchymal transition; TRIM21-mediated K48-linked ubiquitination of CCT6A suppresses this progression 4. In colorectal cancer, downregulation of TRIM38 leads to CCT6A accumulation, which stabilizes c-Myc and activates the MYC pathway 5. CCT6A also demonstrates context-dependent protective functions. In idiopathic pulmonary fibrosis, elevated CCT6A is protective; it inhibits HIF-1α-mediated lactate production through VHL-dependent ubiquitination, alleviating fibrosis 6. CCT6A expression correlates with lactate metabolism in IPF and serves as a serum biomarker for disease diagnosis 7. In gastric cancer, cancer-associated fibroblasts secrete exosomal CCT6A to enhance chemoresistance and stemness through β-catenin/c-Myc signaling 8. These findings position CCT6A as a multifunctional protein with therapeutic potential across diverse malignancies.